Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

Table 1 Patient demographics and baseline characteristics

Variable	CET (n=100)	BEV (n=104)	P-value
Age at onset (years)	64.2±9.5	64.5±8.7	0.231
CRC location^a, n (%)			0.331
Left	52 (52.0)	47 (45.2)
Right	48 (48.0)	57 (54.8)
Metastatic sites, n (%)			0.848
Intra-abdominal	25 (25.0)	27 (26.0)
Lung	14 (14.0)	16 (15.4)
Bone	22 (22.0)	26 (25.0)
Live	25 (25.0)	17 (16.3)
Brain	7 (7.0)	9 (8.7)
Other	11 (11.0)	1413.5)
Serum lactate dehydrogenase level, n (%)			0.428
Normal^b	33 (33.0)	29 (27.9)
Above normal	67 (67.0)	75 (72.1)
Portal vein invasion, n (%)			0.733
Yes	67 (67.0)	72 (69.2)
No	33 (33.0)	32 (30.8)
Duration of treatment (months)	27.2±11.4	27.3±12.5	0.106
Hepatic encephalopathy, n (%)	0 (0.0)	0 (0)	1.000
ECOG PS, n (%)			0.860
0	43 (43.0)	46 (44.2)
1	57 (57.0)	58 (55.8)
Number of metastatic sites, n (%)			0.454
3	13 (13.0)	20 (19.2)
> 3	72 (72.0)	68 (65.4)
Unknown	15 (15.0)	16 (15.4)

^aTumours occurring from the cecum to the transverse colon were considered to be right-sided tumours, and those occurring from the splenic flexure to the sigmoid colon were considered to be left-sided tumours [20]. ^bUsing continuous monitoring method: female 100-230 U/L. CET Cetuximab, BEV Bevacizumab, CRC Colorectal cancer, ECOG PS Eastern Collaborative Oncology Group performance status

ISSN: 1471-2407